Publication: 'On-demand' romiplostim therapy in immune thrombocytopenia
| dc.contributor.author | Mitrovic, M. (54972086700) | |
| dc.contributor.author | Elezovic, I. (12782840600) | |
| dc.contributor.author | Suvajdzic-Vukovic, N. (7003417452) | |
| dc.date.accessioned | 2025-06-12T18:43:08Z | |
| dc.date.available | 2025-06-12T18:43:08Z | |
| dc.date.issued | 2016 | |
| dc.description.abstract | What is known and objective Although thrombopoietin receptor agonists are a second-line treatment for refractory immune thrombocytopenia (ITP), we lack guidelines recommending maintenance modality in patients who achieve complete remission (CR). Case summary We report a patient with refractory ITP who achieved CR on romiplostim. Obtaining romiplostim for 6 months of therapy, we decided to try extending this by modifying the standard treatment regimen. Romiplostim was successfully administered 'on-demand', only if the patient's platelet count dropped below 150 × 109/L, over a period of 12 months. What is new and conclusion The strategy of 'on-demand' therapy is a promising procedure for the maintenance of response, lowering costs and improving treatment safety. © 2016 John Wiley & Sons Ltd. | |
| dc.identifier.uri | https://doi.org/10.1111/jcpt.12359 | |
| dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84970939244&doi=10.1111%2fjcpt.12359&partnerID=40&md5=6813ad0d5b5413464ac71d5ecfcb0c02 | |
| dc.identifier.uri | https://remedy.med.bg.ac.rs/handle/123456789/7708 | |
| dc.subject | 'on-demand' therapy | |
| dc.subject | immune thrombocytopenia | |
| dc.subject | thrombopoietin receptor agonists | |
| dc.title | 'On-demand' romiplostim therapy in immune thrombocytopenia | |
| dspace.entity.type | Publication |